Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2019 Jun 22;7(8):2790–2800.e15. doi: 10.1016/j.jaip.2019.06.011

Figure 3.

Figure 3.

LRBA disease symptoms display different responses to abatacept treatment. A, The remission rates for immune dysregulation (ID), chronic diarrhea and lymphoproliferation. B, The comparison of the remission rates of hematological ID (autoimmune hemolytic anemia, immune thrombocytopenia) versus other immune dysregulatory symptomatologies (Diabetes, alopecia, arthritis, demyelinating disease, granulomatous-lymphocytic interstitial lung disease). The remissions are indicated as complete (CR), partial (PR) or non-responsive (NR). The bars are presented as percentages. * p<.01, Chi-square test.